论文部分内容阅读
目的探究伊曲康唑和盐酸特比萘芬序贯法治疗甲真菌病的效果和安全性。方法 120例甲真菌病患者,随机分为观察组和对照组,各60例。对照组给予伊曲康唑进行治疗,观察组给予伊曲康唑和盐酸特比萘芬序贯疗法进行治疗。观察比较两组治疗第3个月及第6个月的疗效及不良反应。结果治疗后第3个月观察组和对照组的治疗总有效率分别为91.67%(55/60)和71.67%(43/60),治疗后第6个月观察组和对照组的治疗总有效率分别为95.00%(57/60)和76.67%(46/60),两组比较差异均具有统计学意义(P<0.05);观察组和对照组的复发率分别为6.67%(4/60)和20.00%(12/60),两组比较差异有统计学意义(P<0.05);观察组的不良反应发生情况和对照组相比,差异无统计学意义(P>0.05)。结论对甲真菌病采用伊曲康唑与特比萘芬序贯疗法进行治疗,具有明显的治疗效果,安全可靠,适合推广。
Objective To investigate the efficacy and safety of itraconazole and terbinafine hydrochloride sequential therapy in the treatment of onychomycosis. Methods 120 patients with onychomycosis were randomly divided into observation group and control group, with 60 cases in each. The control group was given itraconazole for treatment, and the observation group was treated with itraconazole and terbinafine hydrochloride sequential therapy. The curative effects and adverse reactions of the third and sixth months of treatment in both groups were observed and compared. Results The total effective rates of the observation group and the control group were 91.67% (55/60) and 71.67% (43/60) respectively at the third month after the treatment. In the sixth month after the treatment, the total effective rates of the observation group and the control group were (57/60) and 76.67% (46/60) respectively, the differences between the two groups were statistically significant (P <0.05). The recurrence rates of the observation group and the control group were 6.67% (4/60 ) And 20.00% (12/60), respectively. The differences between the two groups were statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion It is safe and reliable to treat onychomycosis with itraconazole and terbinafine sequential therapy, which is suitable for promotion.